Epidiolex Advisory Committee Appears To Be Covering US FDA's Bases, But Liver Injury Concerns Persist

17 Apr 2018

• By Michael Cipriano

Panel for first-ever marijuana derivative will discuss safety issues, including link to transaminase elevations, but low potential for abuse and strong efficacy suggest a smooth route to approval.

Airliner in flight — It looks like clear skies for GW Pharmaceuticals's childhood epilepsy drug Epidiolex (cannabidiol).

Epidiolex Advisory Committee Appears To Be Covering US FDA's Bases, But Liver Injury Concerns Persist

More from US FDA Performance Tracker

More from Regulatory Trackers